BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.

被引：7
|
作者：
Mettu, Niharika B.
Niedzwiecki, Donna
Boland, Patrick Mckay
Fakih, Marwan
Arrowood, Christy
Bolch, Emily
Hurwitz, Herbert
Grothey, Axel
机构：
[1] Duke Univ, Durham, NC USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] City Hope Natl Med Ctr, Duarte, CA USA
[5] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.TPS873
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS873
引用
收藏
页数：1
相关论文
共 50 条
  • [1] BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study
    Mettu, N. B.
    Twohy, E.
    Ou, F-S.
    Halfdanarson, T. R.
    Lenz, H. J.
    Breakstone, R.
    Boland, P. M.
    Crysler, O.
    Wu, C.
    Grothey, A.
    Nixon, A. B.
    Bolch, E.
    Niedzwiecki, D.
    Fruth, B.
    Schweitzer, B.
    Elsing, A.
    Hurwitz, H.
    Fakih, M. G.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Ervin, Thomas J.
    Senzer, Neil N.
    Richards, Donald A.
    Firdaus, Irfan
    Lockhart, A. Craig
    Cohn, Allen Lee
    Saleh, Mansoor N.
    Gardner, Lesa R.
    Sportelli, Peter
    Eng, Cathy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)
    Kang, Y.
    Ohtsu, A.
    Van Cutsem, E.
    Rha, S. Y.
    Sawaki, A.
    Park, S.
    Lim, H.
    Wu, J.
    Langer, B.
    Shah, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [4] Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
    Rugo, Hope S.
    Stopeck, Alison T.
    Joy, Anil A.
    Chan, Stephen
    Verma, Shailendra
    Lluch, Anna
    Liau, Katherine F.
    Kim, Sinil
    Bycott, Paul
    Rosbrook, Brad
    Bair, Angel H.
    Soulieres, Denis
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2459 - 2465
  • [5] Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
    Gorbunova, Vera
    Beck, Thaddeus
    Hofheinz, Ralf
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Hochster, Howard S.
    Hart, Lowell L.
    Firdaus, Irfan
    Mace, Joseph Ronald
    McFarlane, Joshua Jemison
    Kozloff, Mark
    Catenacci, Daniel Virgil Thomas
    Hsu, Jessie J.
    Hack, Stephen Paul
    Shames, David S.
    Phan, See-Chun
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [7] Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma
    Kindler, Hedy L.
    Karrison, Theodore G.
    Gandara, David R.
    Lu, Charles
    Krug, Lee M.
    Stevenson, James P.
    Jaenne, Pasi A.
    Quinn, David I.
    Koczywas, Marianna N.
    Brahmer, Julie R.
    Albain, Kathy S.
    Taber, David A.
    Armato, Samuel G., III
    Vogelzang, Nicholas J.
    Chen, Helen X.
    Stadler, Walter M.
    Vokes, Everett E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) : 2509 - 2515
  • [8] Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy
    Mark Clemons
    Anil A. Joy
    Radhi Abdulnabi
    Mauricio Kotliar
    Jodi Lynch
    Johan P. Jordaan
    Neill Iscoe
    Karen Gelmon
    Breast Cancer Research and Treatment, 2010, 124 : 177 - 186
  • [9] Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy
    Clemons, Mark
    Joy, Anil A.
    Abdulnabi, Radhi
    Kotliar, Mauricio
    Lynch, Jodi
    Jordaan, Johan P.
    Iscoe, Neill
    Gelmon, Karen
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (01) : 177 - 186
  • [10] PHASE II STUDY OF BEVACIZUMAB plus OXALIPLATIN PLUS CAPECITABINE FOLLOWED BY BEVACIZUMAB plus ERLOTINIB AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
    Munoz, A.
    Pericay, C.
    Llorente, B.
    Alonso, V
    Duenas, R.
    Roca, J.
    Rivera, F.
    Falco, E.
    Alvarez, I
    Salud, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 73 - 74
12345